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| INTRODUC TION
In China, Schistosomiasis japonicum has been one of the most dangerous parasitic diseases for more than 2000 years. 1 For decades, praziquantel has been the only drug widely used for the clinical treatment and chemotherapy of Schistosomiasis japonicum in China. Although the application of praziquantel has greatly reduced the number of infected people, potential resistance against praziquantel limits its use. According to the survey data of 2013, there were still more than 185 000 cases of schistosomiasis and approximately 68 million individuals at risk of infection in China. 2 Considering the difficulty in blocking the transmission of S. japonicum with the sole use of praziquantel, looking for more effective candidates against S. japonicum infection is urgent. Recently, many researchers have been interested in the study of the vaccine of schistosomiasis.
Since Niels Kaj Jerne proposed the immune network theory, 3 it has been widely demonstrated that anti-idiotypic antibody strategy can be used to mimic cytokines by mimicking its receptor binding epitopes and the kind of anti-idiotypic antibody the "internal image" of antigen. Taking advantage of their exquisite specificity and high affinity, anti-idiotypic antibodies have been used as a strong tool in the treatment of infectious diseases and antipathologic vaccine research. 4 NP30 is the anti-idiotypic antibody of Schistosoma japonicum gut-associated antigen (GAA), which is a kind of IgM secreted by the hybridoma cells, according to Guan. 5 Based on the theory of the immune network, NP30 belongs to the family of β-class antiidiotype antibodies, which not only bind to the paratope but also represent a three-dimensional inversion of the nominal antigen and can therefore be used as surrogate antigens, for example for further immunizations or in ligand-binding assay applications. 6 In addition to being an "antigen reagent" in the diagnostic assays of Schistosomiasis japonicum for years in China, NP30 has also induced a protection rate of 50.46% against the challenge of Schistosoma japonicum cercariae. 7, 8 The transfer of NP30 results in smaller granulomas around parasite eggs and lower portal pressure in vivo, which suggested that the anti-idiotypic antibody had the potential for the treatment of schistosome infection through an immune regulation mechanism. Nevertheless, to date, there are few reports on monoclonal anti-idiotypic antibodies for the vaccination of schistosomiasis due to the shortage of related research on mechanisms. 5 Depending on the production of many different associated antigens, Schistosoma japonicum stimulates the secretion of some proinflammatory cytokines to induce Th1 and Th2 cells, which play key roles in the infection immune responses. 9 During the acute stage of 
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| Mice, parasites and infection
| Cell preparation
| Bone marrow-derived DC (BMDC)
Bone marrow cells were flushed from the femurs and tibias of BALB/c mice, RBC were lysed with Tris-ammonium chloride buffer, and the remaining cells were cultured at a concentration of 1 × 106 cells/ml in 10 mL of complete-RPMI 1640 medium containing 10% heat-inactivated FBS, 100 U/mL penicillin, 100 mg/mL streptomycin with 10 ng/mL GM-CSF and 5 ng/mL IL-4 (PeproTech, Rocky Hill, NJ, USA 
| BMDC-NP30 cocultures
BMDCs were cultured with negative control (100 μg/mL), NP30
(100 μg/mL), SEA (20 μg/mL) or LPS (1 μg/mL; Sigma-Aldrich, St. 
| DC-T cell-NP30 cocultures
Single-cell suspensions were prepared with the spleens taken from 
| Flow cytometric analysis of NP30 binding to DCs and cell surface molecule expression by DCs
| Statistical analysis
One-way ANOVA was used to determine the statistical analysis of the differences between groups. P values of <.05 were considered significant and were calculated with GraphPad Prism 5.0.
| RE SULTS
| NP30 binding to DC in vitro
In 
| CD86 and MHCII expressions on DCs are upregulated following stimulation with NP30 in vitro
To detect whether NP30 exerts effects on DCs, the expressions of shown as the mean of four experiments+standard error of the mean. *P < .05 and **P < .01 compared to control group mice be used. Previously, we used a one-step immunization method and hybridoma technique to produce NP30, which was proven as an internal image anti-idiotypic monoclonal antibody of GAA of S. japonicum by ELISA. Our previous studies suggested that NP30
| D ISCUSS I ON
was not only a potential vaccine candidate against S. japonicum but also had potential for the treatment of schistosomiasis. 5 Although we have already noticed that NP30 has the ability to improve Th1 and Th2 differentiation, these results are far from a satisfactory answer to the question of how NP30 produces significant protection to S. japonicum.
During the past few years, many studies have proven that through the expression of chemokines and the secretion of cytokines, the responses of Th17 cells dominate and play key roles in the host defence in response to S. japonicum. 15, 16 Because Th17 has become an important supplement to Th1/Th2 paradigm, 10 we must ask the question of whether or not NP30 can direct Th17 differentiation. To further clarify the mechanism that leads to Th17 cell differentiation after exposure to NP30, we used BMDCs, which were cultured with NP30, SEA or LPS in vitro. BMDC exposure to LPS induced an increase in the expressions of costimulatory (CD40, CD80 and CD86) molecules. NP30 enhanced the expressions of CD86 and MHCII even higher than LPS; however, significant differences in CD40 and CD80 expressions between the NP30 treatment group and control group were not observed. Previous articles reported that SEA stimulated a minor increase in MHCII on DC, but not a major enhancement Recently, some studies have revealed that mice deficient in both CD86 and CD80 failed to stimulate the differentiation of Th17, although the mechanisms are still not clear. 30 However, another report indicated that CD86 but not CD80 enhanced the secretion of IL-17, and the blockade of CD86 significantly suppressed splenocyte IL-17 production. 31 Our data suggest that NP30 stimulates the expression of CD86, but not CD80, in DCs and induces Th17 and Th2 differen- However, the mechanism should be clarified in further studies.
It is well known that
In summary, the present study indicates that NP30 stimulates naïve CD4 + T cell differentiation by modulating DC costimulatory molecule expression and cytokine production, leading to an upregulation of the nonpathologic Th17-mediated immune response. These findings may increase our understanding of the role of NP30 as a potential therapeutic target.
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